In biopharma, it sometimes makes sense for companies to spend a lot of money on buying or developing technical capabilities that seem to be counterproductive at first glance. For instance, on April 5, Merck (NYSE: MRK) spent $208 million to acquire a business called Abceutics, which is developing a technology ...
motleyfoolusx:mrk
According to some new data revealed by Moderna (NASDAQ: MRNA) at the American Association for Cancer Research Annual Meeting on April 8, the biotech responsible for the Spikevax coronavirus vaccine may have another blockbuster drug in the works, this time a personalized cancer vaccine (PCV) for head ...
motleyfoolusx:mrnausx:mrk
Dividends can provide a steady stream of income to shareholders, but only if the dividend-paying company maintains or increases its payouts over the years. Unfortunately, not every dividend payer is capable of doing so. Plenty suspend or decrease their dividends when economic or company-specific troubles ...
motleyfoolusx:jnjusx:mrk
Investors are enjoying the ongoing bull run. The S&P 500 and Nasdaq Composite recently hit all-time highs. Though that's pretty exciting, bull markets don't last forever. Equities that can perform well in good times are great. Those that can perform well over the long run, through bull and bear markets, ...
motleyfoolusx:mrkusx:mdt